Comparing Bluebird Bio and Novavax: Evaluating Biotech Companies for Investment
Saturday, 13 April 2024, 20:22
Who wins this face-to-face between two beaten-down biotechs?
If there is one thing Bluebird Bio (NASDAQ: BLUE) and Novavax (NASDAQ: NVAX) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop catastrophically in recent years. Bluebird's stock is down by 91% in the past three years, while Novavax's has declined by 97%.
The case for Bluebird Bio
- Bluebird Bio has three approved products on the market, with Lyfgenia showing promise in treating SCD.
- The company's innovative gene editing therapies target a significant patient population.
- Bluebird Bio's access to QTCs and financial stability provide a strong foundation for growth.
The case for Novavax
- Novavax stands out for its success in the COVID-19 vaccine market and revenue generation.
- The biotech plans to launch a combination vaccine and continues to focus on innovation.
- Recent agreements and cash reserves position Novavax for future growth.
Conclusion: Despite risks, Bluebird Bio's potential in gene editing makes it a more promising investment compared to Novavax.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.